NeuroSense Therapeutics Shares Move Sharply Higher; Traders Circulate Presentation Slide Saying PrimeC ‘Significantly Alters Key ALS Biomarkers’
https://docs.publicnow.com/viewDoc?hash_primary=E643C899EAD84D83637D61C470FEB3BAE9F37120
Health Canada Clears Cutera’s AviClear
https://www.businesswire.com/news/home/20220713005256/en/
The Daily Biotech Pulse: AstraZeneca’s COVID-19 Vaccine As Effective As mRNA Shots, Humanigen’s Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth’s Alzheimer’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the
Comera Life Sciences Announces Preclinical Topline Safety Results Of Lead SQore Excipient
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient
Humanigen’s Lenzilumab Disappoints In NIH-Backed COVID-19 Study
Humanigen Inc (NASDAQ: HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.
Enveric Biosciences Advances Drug Development For Mental Health Indications And Intellectual Property Portfolio
-- Advancing to IND-enabling studies with multiple drug candidates --
-- Enveric’s Growing Patent Portfolio Validated --
Endo Weighing Chapter 11 Filing Before Junior Creditors, Opioid Settlements: Report
Endo International Plc (NASDAQ:ENDP) is considering bankruptcy filing to restructure its more than $8 billion of debt and several…
Pluristem Reports Topline Results From Its Phase III Study Of Muscle Regeneration Following Hip Fracture Surgery
Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) (“Pluristem” or the “Company”), a leading biotechnology company, today announced topline results from its multinational double-blind,
Vaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study
Vaxcyte (NASDAQ: PCVX) completed patient enrollment in the Phase 2 portion of the ongoing Phase 1/2 proof-of-concept study evaluating VAX-24 in healthy adults 50 to 64 years of age.